Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2003

View Archived Issues

Dutasteride in BPH and prostate cancer

Milkhaus completes enrollment in expanded phase II trial with ML-04

Neose and GSK enter into license agreement

The effects of Y-27632 in models of erectile dysfunction and overactive bladder

Eculizumab reported effective in paroxysmal nocturnal hemoglobinuria

Second-generation adhesion barrier prevents formation of postoperative pleural adhesions in sheep

Potential use of GERD medications as adjunctive therapy in asthma

Lamotrigine as maintenance therapy in bipolar disorder

Improved resolution of cervical neoplasia found with ZYC-101a

Egis presents two series of anxiolytic and cognition-enhancing agents

New CDK2/CDK4 inhibitors with utility in cancer under study at Cyclacel

Bayer claims a series of ECE inhibitors for use in cardiovascular disorders

Japan Tobacco designs new anti-HIV agents

Pyrimidine-based insulin secretagogues prepared and tested at Yamanouchi

AstraZeneca claims delta opioid agonists and therapeutic applications thereof

Novel CETP inhibitors identified by Bayer scientists

Putative repinotan metabolites and their use in stroke and brain trauma

Quinoline NPY antagonists under study at Roche

AVP-8C1 effective in neutralizing key anthrax toxin in preclinical models

FDA approves more convenient formulation of Viracept

Advectus reports preliminary results for preclinical brain cancer trials

Australian authorities approve Iressa for NSCLC

Forest seeks label expansion for Lexapro to include panic disorder

Hepavir B enters the clinic

Japanese rights to NBI-6024 returned to Neurocrine

Zealand Pharma and Wyeth to codevelop ZP-123

Inhibition of MEK1/2 attenuates ischemia-induced neuronal injury in neonatal pigs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...